why Clover Health Investments Corp [CLOV] is a Good Choice for Investors After New Price Target of $4.67

Clover Health Investments Corp [NASDAQ: CLOV] loss -2.45% or -0.08 points to close at $3.19 with a heavy trading volume of 3047000 shares.

The daily chart for CLOV points out that the company has recorded 151.26% gains over the past six months.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

If we look at the average trading volume of 7.09M shares, CLOV reached to a volume of 3047000 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Clover Health Investments Corp [CLOV]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLOV shares is $4.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLOV stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Craig Hallum have made an estimate for Clover Health Investments Corp shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 17, 2024. While these analysts kept the previous recommendation, UBS raised their target price to Neutral. The new note on the price target was released on October 07, 2024, representing the official price target for Clover Health Investments Corp stock. Previously, the target price had yet another drop from $7 to $3, while Cowen kept a Market Perform rating on CLOV stock.

The Average True Range (ATR) for Clover Health Investments Corp is set at 0.17, with the Price to Sales ratio for CLOV stock in the period of the last 12 months amounting to 1.01. The Price to Book ratio for the last quarter was 4.51.

Trading performance analysis for CLOV stock

Clover Health Investments Corp [CLOV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.19. With this latest performance, CLOV shares dropped by -4.57% in over the last four-week period, additionally plugging by 151.26% over the last 6 months – not to mention a rise of 221.61% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLOV stock in for the last two-week period is set at 45.03, with the RSI for the last a single of trading hit 44.67, and the three-weeks RSI is set at 44.95 for Clover Health Investments Corp [CLOV]. The present Moving Average for the last 50 days of trading for this stock 3.56, while it was recorded at 3.21 for the last single week of trading, and 2.15 for the last 200 days.

Clover Health Investments Corp [CLOV]: A deeper dive into fundamental analysis

Clover Health Investments Corp’s liquidity data is similarly interesting compelling, with a Current Ratio set at 1.55.

Clover Health Investments Corp [CLOV]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CLOV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Clover Health Investments Corp go to 19.10%.

An analysis of Institutional ownership at Clover Health Investments Corp [CLOV]

There are presently around $20.18%, or 21.31%% of CLOV stock, in the hands of institutional investors. The top three institutional holders of CLOV stocks are: VANGUARD GROUP INC with ownership of 17.35 million shares, which is approximately 3.5662%. RENAISSANCE TECHNOLOGIES LLC, holding 11.27 million shares of the stock with an approximate value of $$13.86 million in CLOV stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $$11.73 million in CLOV stock with ownership which is approximately 1.9613%.